SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 0.01 |
| Enterprise Value ($M) | -40.07 |
| Book Value ($M) | 46.62 |
| Book Value / Share | 0.89 |
| Price / Book | 0.00 |
| NCAV ($M) | 31.32 |
| NCAV / Share | 0.60 |
| Price / NCAV | 0.00 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.43 |
| Return on Assets (ROA) | -0.22 |
| Return on Equity (ROE) | -0.30 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.69 |
| Current Ratio | 3.04 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 52.22 |
| Assets | 67.51 |
| Liabilities | 20.89 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 31.91 |
| Operating Income | -12.37 |
| Net Income | -26.08 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -26.26 |
| Cash from Investing | -0.55 |
| Cash from Financing | -4.19 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Similar Companies | |
|---|---|
| ELTP – Elite Pharmaceuticals, Inc. | ELVAF – Evolva Holding SA |
| EMMA – Emmaus Life Sciences, Inc. | ENZN – Enzon Pharmaceuticals, Inc. |
| ERGO – Entia Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io